Abstract:Rheumatoid arthritis (RA) is a debilitating joint disease characterized by chronic inflammation, pathologic alteration of fibroblast‑like synoviocytes (FLS), destruction of cartilage and bone, and the formation of an invasive pannus. RA‑FLS exhibit increased proliferation and resistance to apoptosis. The retinoid X receptor (RXR) has a role in regulating cell cycle, differentiation and apoptosis, and agonism of RXR has been investigated as a treatment strategy in several types of cancer. However, there is little research on the effects of RXR agonism in other diseases. Bexarotene is a novel selective RXR ligand used in the treatment of T‑cell lymphoma. In the present study, bexarotene was used to investigate the involvement of RXR in tumor necrosis factor‑α (TNF‑α)‑induced RA conditions in human FLS. To the best of our knowledge, this is the first time that RXR has been demonstrated to be expressed in FLS and to be downregulated in response to TNF‑α stimulation. The present study also demonstrated that bexarotene exerted an anti‑inflammatory effect by downregulating expression of interleukin (IL)‑6, IL‑8, monocyte chemoattractant protein‑1, and high mobility group box‑1. Notably, bexarotene also rescued the TNF‑α‑induced downregulation of the anti‑inflammatory cytokines IL‑4 and transforming growth factor‑β1. Bexarotene treatment exhibited a potential protective effect against cartilage degradation by downregulating the expression of matrix metalloproteinase (MMP)‑1, MMP‑3 and MMP‑13. In addition, the present results demonstrated that the effects of bexarotene were mediated through the p38 mitogen‑activated protein kinase/nuclear factor‑κB pathway, via inhibition of p38 protein and the inhibitor α of κB phosphorylation. Taken together, the present findings demonstrated the potential of RXR agonism using bexarotene as a treatment against the development and progression of RA.

RXR Signaling Targeted Cancer Therapy

Bexarotene: a Promising Anticancer Agent

Targeting Truncated RXRα for Cancer Therapy.

Rexinoid Inhibits Nrf2-Mediated Transcription Through Retinoid X Receptor Alpha

Regulation of the Nongenomic Actions of Retinoid X Receptor-Α by Targeting the Coregulator-Binding Sites

Danthron Functions as a Retinoic X Receptor Antagonist by Stabilizing Tetramers of the Receptor

The Function of Retinoid X Receptor Α in Cancer Cells

Emerging Roles of Bexarotene in the Prevention, Treatment and Anti-Drug Resistance of Cancers

Preventive and Therapeutic Effects of the Retinoid X Receptor Agonist Bexarotene on Tumors.

Therapeutic modulation of retinoid X receptors – SAR and therapeutic potential of RXR ligands and recent patents

Recent Progress in the Design and Discovery of RXR Modulators Targeting Alternate Binding Sites of the Receptor

RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2.

Retinoid X receptor ligands: a patent review (2007 – 2013)

Oncogenic potential of truncated RXRα during colitis-associated colorectal tumorigenesis by promoting IL-6-STAT3 signaling

The retinoid X receptor has a critical role in synthetic rexinoid-induced increase in cellular all- trans -retinoic acid

A review of the molecular design and biological activities of RXR agonists

Retinoid X Receptor Heterodimers in Hepatic Function: Structural Insights and Therapeutic Potential

Activation of RXR by Bexarotene Inhibits Inflammatory Conditions in Human Rheumatoid Arthritis Fibroblast‑like Synoviocytes.

TRC4, an Improved Triptolide Derivative, Specifically Targets to Truncated Form of Retinoid X Receptor-Alpha in Cancer Cells.

RXRα provokes tumor suppression through p53/p21/p16 and PI3K-AKT signaling pathways during stem cell differentiation and in cancer cells

Identification of Biomarkers Modulated by the Rexinoid Lgd1069 (bexarotene) in Human Breast Cells Using Oligonucleotide Arrays